Literature DB >> 16585213

Regeneration and tolerance factor: a novel mediator of glioblastoma-associated immunosuppression.

Patrick Roth1, Steffen Aulwurm, Isabella Gekel, Dagmar Beier, Roxanne G Sperry, Michel Mittelbronn, Richard Meyermann, Kenneth D Beaman, Michael Weller, Jörg Wischhusen.   

Abstract

Regeneration and tolerance factor (RTF) was originally identified in placenta where it is thought to be essential for fetal allograft survival. Here we report that RTF mRNA and protein are also expressed in human glioma cells in vitro and in vivo. Suppression of RTF expression by RNA interference promotes the lysis of glioma cells by natural killer (NK) and T cells in vitro. Moreover, RTF-depleted glioma cells are less tumorigenic than control cells in nude mice in vivo. Depletion of NK cells in these animals abolished this effect. RTF is thus a novel aberrantly expressed molecule which confers immune privilege to human malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16585213     DOI: 10.1158/0008-5472.CAN-05-3062

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Immunosuppressive mechanisms in glioblastoma.

Authors:  Edjah K Nduom; Michael Weller; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

Review 2.  Microenvironmental clues for glioma immunotherapy.

Authors:  Michael Platten; Katharina Ochs; Dieter Lemke; Christiane Opitz; Wolfgang Wick
Journal:  Curr Neurol Neurosci Rep       Date:  2014-04       Impact factor: 5.081

3.  Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.

Authors:  Arpita Kulshrestha; Gajendra K Katara; Jordyn Ginter; Sahithi Pamarthy; Safaa A Ibrahim; Mukesh K Jaiswal; Corina Sandulescu; Ramayee Periakaruppan; James Dolan; Alice Gilman-Sachs; Kenneth D Beaman
Journal:  Mol Oncol       Date:  2016-01-29       Impact factor: 6.603

Review 4.  NK cells in the brain: implications for brain tumor development and therapy.

Authors:  Agisilaos Balatsoukas; Filippo Rossignoli; Khalid Shah
Journal:  Trends Mol Med       Date:  2022-01-22       Impact factor: 11.951

5.  Vacuolar ATPase 'a2' isoform exhibits distinct cell surface accumulation and modulates matrix metalloproteinase activity in ovarian cancer.

Authors:  Arpita Kulshrestha; Gajendra K Katara; Safaa Ibrahim; Sahithi Pamarthy; Mukesh K Jaiswal; Alice Gilman Sachs; Kenneth D Beaman
Journal:  Oncotarget       Date:  2015-02-28

6.  Breast cancer associated a2 isoform vacuolar ATPase immunomodulates neutrophils: potential role in tumor progression.

Authors:  Safaa A Ibrahim; Gajendra K Katara; Arpita Kulshrestha; Mukesh K Jaiswal; Magdy A Amin; Kenneth D Beaman
Journal:  Oncotarget       Date:  2015-10-20

7.  Cell growth inhibition and apoptotic effects of a specific anti-RTFscFv antibody on prostate cancer, but not glioblastoma, cells.

Authors:  Foroogh Nejatollahi; Payam Bayat; Bahareh Moazen
Journal:  F1000Res       Date:  2017-02-17

Review 8.  CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.

Authors:  Michael C Burger; Congcong Zhang; Patrick N Harter; Annette Romanski; Florian Strassheimer; Christian Senft; Torsten Tonn; Joachim P Steinbach; Winfried S Wels
Journal:  Front Immunol       Date:  2019-11-14       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.